Stay updated on Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page.

Latest updates to the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page
- Check7 days agoChange DetectedFooter metadata and indexing terms were expanded to include IPD sharing, FDA-regulated status, and additional related terms for indexing and search. No core study content or eligibility criteria were altered.SummaryDifference100%

- Check14 days agoChange DetectedCore sections including the Study Overview, locations and contacts, and study status were removed, leaving less information about the EV-103 urothelial cancer trial.SummaryDifference20%

- Check21 days agoChange DetectedThe page’s revision tag was updated from v3.5.3 to v3.5.4, signaling a version update to the study record page rather than a substantive content change.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check43 days agoChange DetectedThe page’s revision/version indicator has been updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check50 days agoChange DetectedThe page revision was updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check72 days agoChange DetectedThe study EV-103 (NCT03288545) was terminated by the sponsor after meeting enrollment targets and primary objectives, with data collected for planned regulatory filings. The page updates recruitment status to reflect termination, including removal of the 'Active, not recruiting' designation and related dates.SummaryDifference0.2%

Stay in the know with updates to Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page.